Literature DB >> 20048377

Cancer therapy costs influence treatment: a national survey of oncologists.

Peter J Neumann1, Jennifer A Palmer, Eric Nadler, Chihui Fang, Peter Ubel.   

Abstract

A national survey of medical oncologists indicates that rising cancer treatment costs are influencing clinical practice, even as oncologists tend not to communicate with patients about costs. The survey shows that 84 percent of oncologists say that patients' out-of-pocket spending influences treatment recommendations. Only 43 percent always or frequently discuss costs with patients. Among those surveyed, 79 percent favor more comparative effectiveness research; 80 percent support more cost-effectiveness data, although only 42 percent feel well prepared to interpret it. The results suggest that physicians support federally funded comparative effectiveness research but that they wish to retain a central role in making decisions about how and when to use expensive cancer treatments. The results also support educating physicians about cost-effectiveness and how to communicate with patients regarding cost.

Entities:  

Mesh:

Year:  2010        PMID: 20048377     DOI: 10.1377/hlthaff.2009.0077

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  53 in total

1.  National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008.

Authors:  Didem S M Bernard; Stacy L Farr; Zhengyi Fang
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

2.  Physicians' attitudes about communicating and managing scientific uncertainty differ by perceived ambiguity aversion of their patients.

Authors:  David B Portnoy; Paul K J Han; Rebecca A Ferrer; William M P Klein; Steven B Clauser
Journal:  Health Expect       Date:  2011-08-12       Impact factor: 3.377

3.  Racial and ethnic disparities in cost-related medication non-adherence among cancer survivors.

Authors:  Minjee Lee; Ramzi G Salloum
Journal:  J Cancer Surviv       Date:  2015-11-30       Impact factor: 4.442

4.  The financial burden of cancer patients: time to stop averting our eyes.

Authors:  Barry R Meisenberg
Journal:  Support Care Cancer       Date:  2015-02-26       Impact factor: 3.603

5.  Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D.

Authors:  Amy J Davidoff; Franklin B Hendrick; Amer M Zeidan; Maria R Baer; Bruce C Stuart; Rahul A Shenolikar; Steven D Gore
Journal:  J Oncol Pract       Date:  2015-01-06       Impact factor: 3.840

6.  Financial burden experienced by patients undergoing treatment for malignant gliomas.

Authors:  Priya Kumthekar; Becky V Stell; Daniel I Jacobs; Irene B Helenowski; Alfred W Rademaker; Sean A Grimm; Charles L Bennett; Jeffrey J Raizer
Journal:  Neurooncol Pract       Date:  2014-05-05

Review 7.  Cost, coverage, and comparative effectiveness research: the critical issues for oncology.

Authors:  Steven D Pearson
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

8.  Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.

Authors:  Rajabali Daroudi; Mehrzad Mirzania; Kazem Zendehdel
Journal:  Int J Health Policy Manag       Date:  2015-10-20

9.  Cost of contralateral prophylactic mastectomy.

Authors:  Ashish A Deshmukh; Scott B Cantor; Melissa A Crosby; Wenli Dong; Yu Shen; Isabelle Bedrosian; Susan K Peterson; Patricia A Parker; Abenaa M Brewster
Journal:  Ann Surg Oncol       Date:  2014-05-09       Impact factor: 5.344

10.  Oncologist Support for Consolidated Payments for Cancer Care Management in the United States.

Authors:  Siva Narayanan; Emily Hautamaki
Journal:  Am Health Drug Benefits       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.